BME100 f2015:Group6 8amL1

From OpenWetWare
Revision as of 09:46, 2 September 2015 by Blake T. Browning (talk | contribs) (→‎OUR TEAM)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
BME 100 Fall 2015 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help


OUR TEAM

Name: Blake Browning
Name: Kianna Browning
Name: Colten Hedrick
Name: Zachery Humphreys
Name: Cameron Mcallister
Name: Your name

LAB 1 WRITE-UP

Independent and Dependent Variables

The independent variable is the dose of lipopolysaccharide, as it is what is being changed from group to group. The dependent variable is the inflammotin levels in the subjects, as a change is expected depending on the independent variable, the dose of lipopolysaccharide.


Experimental Design

Groups
We will have 12 groups. 6 will need the lipopolysaccharide and 6 will not. This will allow us to test inflammotin levels as we increase the dosage of lipopolysaccharide in increments of 2 mg starting at 0 mg and ending at 10 mg. The dosage amounts will be 0mg, 2mg, 4mg, 6mg, 8mg, and 10mg; for each dosage amount there will be a group of healthy individuals tested and a group of individuals requiring inflammation medication tested.


Age
The age range we will use will be from 65-75. This is not representative of the entire elderly population, but if we were to include everybody over 65, we would need to have far bigger groups of subjects. Thus, the 10 year range allows us to gather relevant results for a chunk of the elderly community.


Number of subjects per group

We will have 10 subjects per group. This number allows us to stay in our budget, but also gives us enough data points to determine the minimum dosage of lipopolysaccharide needed.




Subject Selection

We will select half of our subjects randomly from a database of people who are above 65-75 years old who are registered to have this medical issue, canceling out any subjects that have contraindications to inflammatories. We will select the other half randomly from another database of healthy individuals from 65-75 years of age. The age range may be a source of bias, but it is far more efficient and cost effective to test an age range that is smaller. If we were to test anybody over the age of 75, we would need far more subjects, thus far more resources.




Sources of Error and Bias

Those who have the need for this medication may produce different results than those who do not, so we’ve put these individuals into different groups (6 groups for those who need inflammatory medication, and 6 for those who do not need inflammatory medication).

The subjects who volunteer for this study may be from a certain class of individuals (more active, less active, etc.). We aim to minimize this directional error by selecting from a database and then getting consent from those selected, as opposed to announcing the experiment and asking for volunteers.

Other medications that a subject is taking may affect the results, thus it will be important to check on the medical history/ medication regimen of each subject. Randomizing the experiment will ensure that each group will have a fairly similar proportion of individuals that have a given medical history/medication regimen.

We are using a relatively small age range, 65-75, so we can only infer these results for patients in this age range.

Unforeseen extraneous variables could affect our results, so we are reducing the effect of this by using a large enough sample size such that not all subjects will be affected by the same extraneous variables. We will, though, give each patient the same instructions on the logistics of the test (time of day taken, possible dietary restrictions, etc.), and will conduct the test with multiple trials throughout a length of time, such as a month.